隶属于 upmc western maryland corp.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
1
100.0%
暂无批准数据
- RenovoRx presented new pharmacokinetic and pharmacodynamic data from its Phase III TIGeR-PaC trial at ASCO GI 2026, demonstrating reduced systemic gemcitabine levels with intra-arterial delivery. - The sub-study of 16 patients showed that TAMP therapy with intra-arterial gemcitabine resulted in increased levels of inactive metabolites and decreased CA 19-9 biomarker levels compared to standard intravenous treatment. - The targeted drug-delivery approach may improve local drug potency while reducing chemotherapy-related side effects for patients with locally advanced pancreatic cancer.
- Phanes Therapeutics will present Phase 1/2 study results of spevatamig (PT886) combined with chemotherapy for frontline treatment of metastatic pancreatic ductal adenocarcinoma at ASCO GI 2026. - This marks the first public release of clinical trial data from the company's ongoing U.S. multi-center TWINPEAK study evaluating the first-in-class bispecific antibody. - Spevatamig targets claudin 18.2 and CD47 and has received FDA orphan drug designation and Fast Track designation for metastatic pancreatic adenocarcinoma treatment. - The presentation will take place on January 9, 2026, with Dr. Anwaar Saeed from University of Pittsburgh Medical Center as the first author.
- Myriad Genetics will launch its Precise MRD assay for limited clinical use in March 2026, starting with breast cancer followed by colorectal and renal cancers later in the year. - The ultrasensitive test demonstrates exceptional performance with 93% baseline sensitivity in breast cancer and 100% baseline detection in colorectal cancer patients. - Clinical studies show the assay can detect circulating tumor DNA at one part-per-million levels, enabling early prediction of treatment response and disease recurrence. - The whole-genome sequencing-based test represents a significant advancement in molecular residual disease monitoring for precision oncology applications.
- Approximately 33% of patients with HR-positive, HER2-negative breast cancer derived clinical benefit from abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitor therapy in the retrospective rAMBER study. - The median duration of treatment with abemaciclib was 4.0 months following disease progression on palbociclib-based treatment, with one patient achieving partial response and seven experiencing stable disease. - Genomic analysis revealed that RB1 alterations were associated with acquired or intrinsic resistance to abemaciclib, while ESR1 alterations were found across all biopsy phenotypes. - The study represents the first evaluation of abemaciclib monotherapy effectiveness after progression on CDK4/6 inhibitors, offering new perspectives on sequential CDK4/6 therapies.
- OCU410 gene therapy demonstrated a 21.4% reduction in geographic atrophy lesion growth in low-dose patients after 6 months compared to untreated fellow eyes. - The phase 1/2 trial showed no serious adverse events during 12-month follow-up, with patients experiencing more than 40% decrease in lesion size and four-line improvement in low luminance visual acuity. - Ocugen's subretinal gene therapy requires only a single surgical intervention, offering a potential "one-and-done" alternative to repeated monthly injections. - Phase 2 enrollment has been completed and phase 3 trials are planned to begin in the first quarter of 2026.
- The MammaPrint 70-gene assay demonstrated significant predictive utility for chemotherapy benefit in hormone receptor-positive, HER2-negative early-stage breast cancer patients, with the strongest benefit observed in High Risk 2 patients. - Patients with MammaPrint High Risk 2 breast cancer showed maximum absolute reduction benefit of 14.2% with chemotherapy, while Low and Ultralow risk categories showed minimal benefit of 1.7% and less than 1.0% respectively. - Real-world evidence from the FLEX study supports using MammaPrint to guide treatment decisions in older patients aged 70 and above, potentially sparing low-risk patients from unnecessary chemotherapy while identifying those who may benefit despite advanced age. - Multivariate analysis confirmed significant interaction between MammaPrint Index and chemotherapy benefit, with pre- or peri-menopausal status significantly associated with greater chemotherapy benefit.
- KAHR Bio will present Phase 2 data on DSP107, a first-in-class bi-specific 4-1BB T-cell engager, combined with atezolizumab for third-line microsatellite stable colorectal cancer at ASCO 2025. - The combination therapy demonstrated anti-tumor activity and extended survival in patients with liver metastases, addressing a significant unmet medical need in MSS-CRC treatment. - DSP107 uniquely converts CD47 signals into 4-1BB activation, engaging both innate and adaptive immunity to overcome the immunotherapy resistance typical of MSS-CRC. - The open-label, multi-center Phase 2 trial enrolled third-line MSS-CRC patients receiving weekly DSP107 infusions at 10 mg/kg plus atezolizumab 1200 mg every three weeks.
• A 26-year-old bone cancer survivor has received the first known transplant of sperm-producing stem cells preserved from his childhood, marking a significant advancement in fertility preservation for pediatric cancer patients. • Approximately one-third of childhood cancer survivors face infertility from treatments, with prepubertal patients having limited options as they cannot bank mature reproductive cells before therapy. • The experimental procedure, developed at the University of Pittsburgh Medical Center, follows successful animal studies and represents a potential breakthrough in oncofertility, though researchers caution results remain uncertain.
- Researchers have identified distinct metabolic signatures in pancreatic cancer patients using quantitative mass spectrometry, potentially offering new pathways for earlier diagnosis and survival prediction. - A metabolomic study revealed specific metabolite ratios as significant predictors of survival outcomes in pancreatic ductal adenocarcinoma (PDAC) patients, with some markers showing perfect accuracy in predicting survival beyond 36 months. - A separate study combining microbial-related metabolites with tumor marker CA19-9 achieved an impressive 0.86 AUC for predicting 2-year pancreatic cancer risk, surpassing traditional diagnostic methods.
- A phase 3 trial showed that adding perioperative atezolizumab to chemotherapy did not significantly improve event-free survival (EFS) in patients with triple-negative breast cancer (TNBC). - The NSABP B-59/GBG-96-GeparDouze trial revealed a non-statistically significant difference in 4-year EFS rates between the atezolizumab/chemotherapy and placebo/chemotherapy groups. - While the addition of atezolizumab boosted pathological complete response rates, it did not translate to an overall survival benefit at 4 years. - Researchers suggest further translational studies to identify TNBC patient subsets that may benefit from checkpoint inhibitors in neoadjuvant/adjuvant therapy.
